US Stock MarketDetailed Quotes
AXSM Axsome Therapeutics
- 91.750
- +0.720+0.79%
Close Sep 12 16:00 ET
- 91.870
- +0.120+0.13%
Post 18:16 ET
4.40BMarket Cap-13943P/E (TTM)
92.783High89.540Low274.96KVolume90.710Open91.030Pre Close25.22MTurnover0.77%Turnover RatioLossP/E (Static)48.00MShares98.40052wk High42.81P/B3.28BFloat Cap55.02052wk Low--Dividend TTM35.77MShs Float109.940Historical High--Div YieldTTM3.56%Amplitude1.940Historical Low91.714Avg Price1Lot Size
Axsome Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 45.60%-30.11M | -818.52%-53.47M | -24.52%-145.08M | -10.15%-30.36M | -135.29%-53.55M | -65.04%-55.35M | 82.17%-5.82M | -7.66%-116.51M | 4.43%-27.56M | 15.01%-22.76M |
| Net income from continuing operations | -18.13%-79.35M | -509.35%-68.36M | -27.84%-239.24M | -61.09%-98.65M | -38.77%-62.2M | -62.09%-67.17M | 71.69%-11.22M | -43.50%-187.13M | -80.24%-61.24M | -28.50%-44.82M |
| Depreciation and amortization | 18.00%1.99M | 10.17%1.83M | 55.25%6.83M | 2.84%1.74M | 3.75%1.74M | 135.24%1.69M | 432.69%1.66M | 5,692.11%4.4M | 319.10%1.69M | 460.48%1.68M |
| Other non cash items | -59.95%2.98M | -177.33%-324K | 1,000.44%53.1M | 878.29%44.21M | 156.22%1.03M | 7,251.92%7.44M | 5,137.50%419K | 395.38%4.83M | 332.72%4.52M | 76,911.49%402K |
| Change In working capital | 272.97%22.88M | 29.29%-6.81M | -219.95%-28.39M | -79.49%3.43M | -183.10%-8.96M | -360.26%-13.23M | -925.24%-9.63M | 7,205.56%23.67M | 1,725.71%16.7M | 418.26%10.79M |
| -Change in receivables | 16.40%-18.91M | 6.75%-6.62M | -51.52%-57.12M | 5.70%-16.41M | -166.21%-11.01M | -39.89%-22.62M | ---7.09M | ---37.7M | ---17.4M | ---4.13M |
| -Change in inventory | 150.19%528K | 78.01%-972K | 15.41%-4.46M | 60.45%-1.8M | 438.89%2.81M | -1,243.48%-1.05M | ---4.42M | -87,816.67%-5.28M | -976,029.03%-4.54M | -14,859.35%-828K |
| -Change in prepaid assets | 131.55%224K | -61.86%-3.92M | -95.06%-5.34M | -307.74%-1.32M | 26.49%-888K | -181.33%-710K | -16.51%-2.42M | -2,755.34%-2.74M | -190.75%-323K | -3,601.25%-1.21M |
| -Change in payables and accrued expense | 268.00%41.04M | 9.03%4.7M | -44.47%38.53M | -41.11%22.94M | -99.26%125K | -9.55%11.15M | 278.56%4.31M | 30,463.44%69.38M | 2,917.70%38.96M | 726.26%16.96M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 45.60%-30.11M | -818.52%-53.47M | -24.52%-145.08M | -10.15%-30.36M | -135.29%-53.55M | -65.04%-55.35M | 82.17%-5.82M | -7.66%-116.51M | 4.43%-27.56M | 15.01%-22.76M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 60.90%-52K | -38.03%-98K | 98.92%-582K | 96.13%-7K | -462.12%-371K | 99.75%-133K | 66.82%-71K | -17,335.71%-53.7M | -40,033.04%-181K | 74.49%-66K |
| Net PPE purchase and sale | 60.90%-52K | -38.03%-98K | 17.09%-582K | 96.13%-7K | -462.12%-371K | 44.81%-133K | 66.82%-71K | -127.92%-702K | -40,033.04%-181K | 74.49%-66K |
| Net business purchase and sale | ---- | ---- | --0 | --0 | ---- | ---- | ---- | ---53M | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 60.90%-52K | -38.03%-98K | 98.92%-582K | 96.13%-7K | -462.12%-371K | 99.75%-133K | 66.82%-71K | -17,335.71%-53.7M | -40,033.04%-181K | 74.49%-66K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -94.16%14.38M | -102.30%-1.19M | 16.32%331.01M | -100.19%-2K | -81.14%33.37M | 226.09%246.08M | 65.79%51.57M | 2,456.89%284.58M | 54.32%1.07M | 40,236.64%176.95M |
| Net issuance payments of debt | -100.62%-186K | -100.30%-163K | 88.89%85M | --0 | --0 | -33.33%30M | --55M | --45M | --0 | --0 |
| Net common stock issuance | ---- | ---- | 6.15%258.75M | --0 | -81.27%33.75M | ---- | ---- | 3,178.15%243.76M | --0 | --180.2M |
| Proceeds from stock option exercised by employees | 2.60%6.74M | 546.25%2.5M | 98.67%12.42M | -59.53%1.15M | 40.89%4.32M | 3,632.95%6.57M | 112.64%387K | 42.00%6.25M | 159.27%2.83M | 598.45%3.06M |
| Net other financing activities | 77.79%-3.44M | 7.77%-3.53M | -141.14%-25.16M | 34.94%-1.15M | 25.65%-4.7M | -584.49%-15.49M | -4,194.38%-3.82M | -1,373.45%-10.43M | -182.54%-1.76M | ---6.32M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -94.16%14.38M | -102.30%-1.19M | 16.32%331.01M | -100.19%-2K | -81.14%33.37M | 226.09%246.08M | 65.79%51.57M | 2,456.89%284.58M | 54.32%1.07M | 40,236.64%176.95M |
| Net cash flow | ||||||||||
| Beginning cash position | 34.45%331.44M | 92.29%386.19M | 132.26%200.84M | 83.09%416.56M | 495.57%437.11M | 191.02%246.52M | 132.26%200.84M | -52.97%86.47M | 98.49%227.52M | -48.03%73.39M |
| Current changes in cash | -108.28%-15.78M | -219.88%-54.75M | 62.06%185.35M | -13.84%-30.37M | -113.33%-20.55M | 1,784.62%190.6M | 2,687.71%45.67M | 217.42%114.37M | 5.23%-26.68M | 679.50%154.13M |
| End cash Position | -27.79%315.66M | 34.45%331.44M | 92.29%386.19M | 92.29%386.19M | 83.09%416.56M | 495.57%437.11M | 191.02%246.52M | 132.26%200.84M | 132.26%200.84M | 98.49%227.52M |
| Free cash flow | 45.64%-30.16M | -809.11%-53.57M | -24.27%-145.66M | -9.46%-30.37M | -136.24%-53.92M | -64.25%-55.48M | 82.07%-5.89M | -8.00%-117.21M | 3.80%-27.74M | 15.58%-22.82M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg